TITLE

The H1N1 vaccine race: Can we beat the pandemic?

AUTHOR(S)
Hébert, Paul C.; MacDonald, Noni
PUB. DATE
October 2009
SOURCE
CMAJ: Canadian Medical Association Journal;10/13/2009, Vol. 181 Issue 8, pE125
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
In this article the authors reflect upon the ability of Canada in proving timely vaccination against the pandemic of H1N1 influenza. They state that the decision of the vaccine licensing authority Health Canada to treat H1N1 virus as a new subtype will delay the timely release of the vaccine and stress on the need for timely release of the vaccine to prevent the epidemic. They suggest quick review of the vaccine should be conducted by Health Canada to protect the high-risk population.
ACCESSION #
44645290

 

Related Articles

  • Healthcare Worker Acceptance of Pandemic (H1N1) 2009 Vaccination, Morocco. Tagajdid, Rida; El Annaz, Hicham; Doblali, Taoufik; Sefiani, Kawtar; Belfquih, Bouchra; Mrani, Saad // Emerging Infectious Diseases;Oct2010, Vol. 16 Issue 10, p1638 

    A letter to the editor is presented about a survey of healthcare workers on the acceptance of pandemic H1N1 2009 vaccination in Morocco conducted from January 15 to February 28, 2010.

  • Determinants of adults' intention to vaccinate against pandemic swine flu. Myers, Lynn B.; Goodwin, Robin // BMC Public Health;2011, Vol. 11 Issue 1, p1 

    Background: Vaccination is one of the cornerstones of controlling an influenza pandemic. To optimise vaccination rates in the general population, ways of identifying determinants that influence decisions to have or not to have a vaccination need to be understood. Therefore, this study aimed to...

  • Vical gets good H1N1 pandemic FLU Vaccine Phase 1.  // Biotech Business;Jun2011, Vol. 24 Issue 6, p7 

    The article discusses the favorable Phase 1 trial of Vical Incorporated's Vaxfectin (R)-formulated vaccine for H1N1 pandemic influenza. It reports that the vaccine generated neutralizing antibodies demonstrating its safety and immunogenicity in humans. Information presented states that the trial...

  • Factors associated with parental acceptance and refusal of pandemic influenza A/H1N1 vaccine in Turkey. Akıs, Sule; Velıpasaoglu, Sevtap; Camurdan, Aysu; Beyazova, Ufuk; Sahın, Figen // European Journal of Pediatrics;Sep2011, Vol. 170 Issue 9, p1165 

    The objective of this study was to investigate the parents' attitudes towards and identify the possible factors associated with pandemic H1N1 vaccine uptake that was recommended to children between 6 months and 5 years of age. A questionnaire exploring the attitudes of parents to H1N1 vaccine...

  • 2009 H1N1 Vaccination in Minnesota. MUSCOPLAT, MIRIAM HALSTEAD; RODDY, MARGARET; PARILLA, ELIZABETH; DAVEY, CYNTHIA S.; FLEEGE, LAURA; WHITE, KAREN; EHRESMANN, KRISTEN // Minnesota Medicine;Sep2013, Vol. 96 Issue 9, p49 

    According to Minnesota Immunization Information Connection (MIIC) data, 23% of Minnesotans were vaccinated against 2009 pandemic H1N1 influenza. We analyzed 2009 H1N1 vaccination data at the ZIP code level to learn more about who received the vaccine between 2009 and 2010. We found significant...

  • Trust in medical organizations predicts pandemic (H1N1) 2009 vaccination behavior and perceived efficacy of protection measures in the Swiss public. Gilles, Ingrid; Bangerter, Adrian; Clémence, Alain; Green, Eva; Krings, Franciska; Staerklé, Christian; Wagner-Egger, Pascal // European Journal of Epidemiology; 

    Following the recent avian influenza and pandemic (H1N1) 2009 outbreaks, public trust in medical and political authorities is emerging as a new predictor of compliance with officially recommended protection measures. In a two-wave longitudinal survey of adults in French-speaking Switzerland,...

  • Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination Ioannidis, John P. A.; Manzoli, Lamberto; De Vito, Corrado; D'Addario, Maddalena; Villari, Paolo // PLoS Clinical Trials;Dec2011, Vol. 6 Issue 12, p1 

    Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among...

  • A Candidate H1N1 Pandemic Influenza Vaccine Elicits Protective Immunity in Mice. Steitz, Julia; Barlow, Peter G.; Hossain, Jaber; Eun Kim; Okada, Kaori; Kenniston, Tom; Rea, Sheri; Donis, Ruben O.; Gambotto, Andrea // PLoS ONE;2010, Vol. 5 Issue 5, p1 

    Background: In 2009 a new pandemic disease appeared and spread globally. The recent emergence of the pandemic influenza virus H1N1 first isolated in Mexico and USA raised concerns about vaccine availability. We here report our development of an adenovirus-based influenza H1N1 vaccine tested for...

  • Factors influencing H1N1 vaccine behavior among Manitoba Metis in Canada: a qualitative study. Driedger, S. Michelle; Maier, Ryan; Furgal, Chris; Jardine, Cindy // BMC Public Health;2015, Vol. 15 Issue 1, p1 

    Background: During the first wave of the H1N1 influenza pandemic in 2009, Aboriginal populations in Canada experienced disproportionate rates of infection, particularly in the province of Manitoba. To protect those thought to be most at-risk, health authorities in Manitoba listed all Aboriginal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics